BioSpace News Archive

Cybrexa Therapeutics announced the Company will regain all rights to CBX-12, a clinical-stage, first-in-class peptide drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells, as its collaboration partner, Exelixis, Inc., has provided a notice of termination for the right to acquire CBX-12.

Ovid Therapeutics Inc. today announced that management will participate in a virtual presentation at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m. ET.

Zomedica Corp. announced that it will be hosting a Virtual Investor Day event on Tuesday, February 13, 2024, starting at 3:00 p.m. ET.

Eli Lilly and Company announced its financial results for the fourth quarter of 2023.

Kraig Biocraft Laboratories, Inc., announces the successful creation of a new recombinant spider silk hybrid.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”) announced today that it has concluded its interaction with the U.S. Food and Drug Administration (“FDA”) on optimizing the development plan for its stroke program which aims to evaluate the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”) delivered using PoNS Therapy® on gait and dynamic balance in chronic stroke survivors.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) today announced the completion of patient enrollment in the safety lead-in portion of the investigator-sponsored Phase 2 trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Element Biosciences, Inc., developer of pioneering technologies to empower science, announced a collaboration with DNAnexus, provider of the Precision Health Data Cloud, to allow customers to stream data from Element’s AVITI™ System directly to their DNAnexus account.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today outlined the global development strategy for its lead gene therapy candidate, ETX101, for the treatment of SCN1A+ Dravet syndrome.